

## Special Issue

# Biomarkers in the "Omics" Era

### Message from the Guest Editors

The rapid development of high-throughput technologies has opened up a new "omics" era providing an unprecedented opportunity for scientists and clinicians to gain deeper insights into cancer molecular mechanisms, even at single cell resolution. The analysis and integration of the data arising from these methodological approaches is revolutionizing daily clinical practice, moving the cancer precision medicine paradigm forward. In this scenario, the identification of tissue and circulating molecular biomarkers with high sensitivity and specificity to be employed for diagnosis, prognosis, and treatment prediction will undoubtedly benefit cancer patients, but only few have been successfully implemented into the clinic. This Special Issue of *BioTech* includes research articles, short reports, and reviews focused on the employment of "omics" (e.g., genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiomics) technologies for cancer biomarker development both at translational and clinical level.

### Guest Editors

Dr. Alfonso Urbanucci

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway

Dr. Simona Tavori

Division of Medical Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy

### Deadline for manuscript submissions

closed (31 July 2022)



## BioTech

an Open Access Journal  
by MDPI

Impact Factor 3.1  
CiteScore 4.8  
Indexed in PubMed



[mdpi.com/si/61890](https://mdpi.com/si/61890)

*BioTech*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biotech@mdpi.com](mailto:biotech@mdpi.com)

[mdpi.com/journal/  
biotech](https://mdpi.com/journal/biotech)





# BioTech

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.1  
CiteScore 4.8  
Indexed in PubMed



[mdpi.com/journal/  
biotech](https://mdpi.com/journal/biotech)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Massimo Negrini  
Department of Morphology, Surgery and Experimental Medicine,  
University of Ferrara, Ferrara, Italy

---

#### Author Benefits

##### High Visibility:

indexed within ESCI (Web of Science), Scopus, PubMed, PMC, Inspec, CAPlus / SciFinder, and other databases.

##### Journal Rank:

JCR - Q2 (Biotechnology and Applied Microbiology)

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 22.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).